Shopping Cart
- Remove All
Your shopping cart is currently empty
PKG drug G1
PKG drug G1 targets PKG Iα C42. PKG drug G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.
Catalog No. T4661Cas No. 374703-78-3
Select Batch
Purity:99.41%
Contact us for more batch information
PKG drug G1
Catalog No. T4661Cas No. 374703-78-3
PKG drug G1 targets PKG Iα C42. PKG drug G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $33 | In Stock | |
| 5 mg | $51 | In Stock | |
| 10 mg | $79 | In Stock | |
| 25 mg | $158 | In Stock | |
| 50 mg | $239 | In Stock | |
| 100 mg | $363 | In Stock | |
| 500 mg | $855 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $56 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "PKG drug G1"
Acefylline
T2205652-37-9
Acefylline (Theophylline-7-acetic acid), a stimulant drug of the xanthine chemical class, acts as an adenosine receptor antagonist. It is combined with diphenhydramine in the pharmaceutical preparation Etanautine to help offset its stimulant effects
- $29
Size
QTY
Staurosporine
Cited
T668062996-74-1
Staurosporine (AM-2282) is a protein kinase inhibitor with ATP-competitive and non-selective inhibitory activity (IC50=6/15/2/3/3000 nM) against PKC, PKA, c-Fgr, phosphorylase kinase and TAOK2. Staurosporine also induces apoptosis.
- $56
Size
QTY
CitedJAK1/2/3 Inhibitor 1
T7750416234-14-3
JAK1/2/3 Inhibitor 1 is a potent protein kinase inhibitor.JAK1/2/3 Inhibitor 1 has antitumor activity that inhibits the growth of a variety of cancer cell lines. It inhibits the growth of cancer cells by binding to the cancer cell backbone and inhibiting the production of new proteins.
- $50
Size
QTY
Capivasertib Cited
T19201143532-39-1
Capivasertib (AZD5363) is a broad-spectrum AKT inhibitor with inhibitory activity against Akt1, Akt2, and Akt3 (IC50=3/7/7 nM) with oral activity. Capivasertib has antitumor activity for the treatment of breast cancer.
- $34
Size
QTY
Cited8-Bromo-cAMP sodium salt Cited
T674776939-46-3
8-Bromo-cAMP sodium salt (8-Br-Camp sodium salt) is a long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase（PKA）, but resistant to degradation by cyclic AMP phosphodiesterase.
- $41
Size
QTY
CitedRo-3306 Cited
T2356872573-93-8
RO-3306 is a selectivity ATP-competitive CDK1 inhibitor (Ki: 20 nM). The selectivity of RO-3306 for CDK1 is >15-fold higher than a diverse panel of human kinases.
- $32
Size
QTY
CitedFasudil hydrochloride Cited
T3060105628-07-7
Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.
- $35
Size
QTY
CitedEllagic acid Cited
T0465476-66-4
Ellagic acid (Gallogen), a thickened tetracyclic natural product, is a potent CK2 inhibitor (IC50=40 nM; Ki=20 nM) with ATP-competitive properties. Ellagic acid is an antioxidant and also possesses antiproliferative activity.
Carbonic AnhydraseCasein KinaseEndogenous MetaboliteHedgehog/SmoothenedPKAPKCReactive Oxygen SpeciesSykTopoisomerase
- $44
Size
QTY
CitedGSK180736A
T3513817194-38-0
GSK180736A is an effective and selective GRK2 inhibitor (IC50: 0.77 μM) and >100-fold selectivity over other GRKs. It is a weak inhibitor of PKA (IC50: 30 μM), but highly effective against ROCK1 (IC50: 100 nM).
- $35
Size
QTY
Daphnetin
T2851486-35-1
Daphnetin (7,8-Dihydroxycoumarin), a natural coumarin derivative, is a protein kinase inhibitor with inhibitory for EGFR (IC50: 7.67 μM), PKA (IC50: 9.33 μM), and PKC (IC50: 25.01 μM), also exhibit anti-oxidant and anti-inflammatory activities.
- $43
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | PKG drug G1 targets PKG Iα C42. PKG drug G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism. |
| In vivo | The absorption rate following oral administration is 80% in rats and >90% in dogs and monkeys. The metabolism of Asimadoline is rapid and appears similar in animals and man. Asimadoline has peripheral anti-inflammatory actions that are partly mediated through increase in joint fluid substance P levels |
| Animal Research | Mice constitutively expressing PKG Iα Cys42Ser are generated on a pure C57BL/6 background. Age-matched and. body weight–matched WT or PKG Iα Cys42Ser KI male mice are used in all studies. Blood pressure and heart rate are. assessed by radio telemetry in conscious freely moving mice. Alzet osmotic mini-pumps are used to deliver. angiotensin II at 1.1 mg/kg per day in some studies. PKG drug G1 is delivered intraperitoneally (3.7-14.8 mg/kg) or. orally (20 mg/kg) in some studies. To deliver PKG drug G1 orally, without stress or risk of dislodging the telemetric. probe catheter, it is provided suspended in water and set in gelatin flavored with sodium saccharin. |
| Molecular Weight | 257.31 |
| Formula | C13H11N3OS |
| Cas No. | 374703-78-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 16.67 mg/mL (64.77 mM)  | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy PKG drug G1 | purchase PKG drug G1 | PKG drug G1 cost | order PKG drug G1 | PKG drug G1 chemical structure | PKG drug G1 in vivo | PKG drug G1 formula | PKG drug G1 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.